Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens

Trial Profile

Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Raltegravir (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top